BridgeMD
New treatment option for Chemotherapy-induced Peripheral Neuropathy (CIPN)
Official title Trial of a Virtual Exercise-based Rehabilitation Program to Treat Persistent Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ClinicalTrials.gov ID: NCT07481149
What this study is testing
- What it's testing
- The purpose of this study is to determine the effectiveness of the EX-CIPN program in reducing the strength of CIPN symptoms and CIPN-related disability and improving the ability to complete everyday activities. This will be done by determining whether it is better to receive the EX-CIPN program or better to receive no additional intervention.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- diagnosed with any type of cancer
- received chemotherapy treatment as part of curative-intent therapy (no minimum dose)
- \>6 months following chemotherapy completion with no current plans for further chemotherapy
- report Grade 1 or higher on the numbness and tingling severity item of the Common Terminology Criteria for Adverse Events (CTCAE) v 5.0
- neuropathic pain 3 or higher on the Neuropathic Pain 4 (DN4) (interview)
You likely can't join if
- currently meeting all recommendations from the physical activity guidelines for cancer survivors
- have any neurological conditions influencing cognition (i.e. dementia, Alzheimer's) and preventing safe or appropriate engagement with exercise...
- have neuropathy that pre-existed chemotherapy receipt (i.e. diabetic neuropathy)
- currently enrolled in other rehabilitation or exercise-based interventions
See the full eligibility criteria
- diagnosed with any type of cancer
- received chemotherapy treatment as part of curative-intent therapy (no minimum dose)
- \>6 months following chemotherapy completion with no current plans for further chemotherapy
- report Grade 1 or higher on the numbness and tingling severity item of the Common Terminology Criteria for Adverse Events (CTCAE) v 5.0
- neuropathic pain 3 or higher on the Neuropathic Pain 4 (DN4) (interview)
- capable of ambulation and transfers (with or without gait/transfer aid) (ECOG score 0-2)
- are able to communicate sufficiently in English to complete intervention, questionnaires, and consent
- have access to and able to operate videoconferencing
- currently meeting all recommendations from the physical activity guidelines for cancer survivors
- have any neurological conditions influencing cognition (i.e. dementia, Alzheimer's) and preventing safe or appropriate engagement with exercise recommendation
- have neuropathy that pre-existed chemotherapy receipt (i.e. diabetic neuropathy)
- currently enrolled in other rehabilitation or exercise-based interventions
The study team makes the final eligibility decision.
Where it's taking place
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.